Overview
Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects
Status:
Completed
Completed
Trial end date:
2010-07-01
2010-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study aims to determine, in obese subjects, the antisecretory effect of a single dose of placebo, rabeprazole 20 mg and omeprazole 20 mg using 24h gastric pH monitoring, in a prospective, monocentre, randomized manner. Monitorings are separated between 6 and10 days. The main outcome criteria of analysis is the percentage of time with gastric pH above 3 during 24hours.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Nantes University HospitalTreatments:
Omeprazole
Rabeprazole
Criteria
Inclusion Criteria:- Helicobacter negative obese subject (BMI 30 to 40),
- 18 to 55 years old,
- normal hepatic biology and morphology (echography)
- Contraceptive methods in women.
Exclusion Criteria:
- Subjects with previous abdominal surgery, with diabetic or immunosuppressive
treatment.